RhumbLine Advisers’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $287K | Buy |
63,585
+1,346
| +2% | +$6.07K | ﹤0.01% | 3010 |
|
|
2025
Q1 | $289K | Buy |
62,239
+448
| +0.7% | +$2.08K | ﹤0.01% | 2910 |
|
|
2024
Q4 | $429K | Buy |
61,791
+9,323
| +18% | +$64.7K | ﹤0.01% | 2768 |
|
|
2024
Q3 | $278K | Buy |
52,468
+4,543
| +9% | +$24.1K | ﹤0.01% | 3066 |
|
|
2024
Q2 | $179K | Buy |
47,925
+1,372
| +3% | +$5.13K | ﹤0.01% | 3284 |
|
|
2024
Q1 | $328K | Buy |
46,553
+1,193
| +3% | +$8.41K | ﹤0.01% | 2936 |
|
|
2023
Q4 | $256K | Sell |
45,360
-243
| -0.5% | -$1.37K | ﹤0.01% | 3060 |
|
|
2023
Q3 | $218K | Buy |
45,603
+578
| +1% | +$2.77K | ﹤0.01% | 3116 |
|
|
2023
Q2 | $308K | Sell |
45,025
-1,148
| -2% | -$7.86K | ﹤0.01% | 2997 |
|
|
2023
Q1 | $360K | Buy |
46,173
+2,324
| +5% | +$18.1K | ﹤0.01% | 2556 |
|
|
2022
Q4 | $334K | Buy |
43,849
+887
| +2% | +$6.76K | ﹤0.01% | 2636 |
|
|
2022
Q3 | $351K | Buy |
42,962
+2,412
| +6% | +$19.7K | ﹤0.01% | 2654 |
|
|
2022
Q2 | $392K | Buy |
40,550
+16,358
| +68% | +$158K | ﹤0.01% | 2620 |
|
|
2022
Q1 | $339K | Buy |
+24,192
| New | +$339K | ﹤0.01% | 2597 |
|
|
2021
Q4 | – | Sell |
-9,233
| Closed | -$206K | – | 3008 |
|
|
2021
Q3 | $206K | Buy |
+9,233
| New | +$206K | ﹤0.01% | 2906 |
|